Trevi Therapeutics

Trevi Therapeutics announces positive results from phase II Prurigo Nodularis trial

Wednesday, October 19, 2016

Trevi Therapeutics, a late-stage clinical development company developing oral NalbuphineER for chronic pruritus conditions, has announced positive results from its phase II trial for the treatment of moderate to severe prurigo nodularis. Prurigo nodularis (PN), a severely pruritic dermatological condition characterized by itchy skin papules and nodules, has significant impact on quality of life and has no approved therapies. Trevi also previously reported statistically significant results from a robust phase II/III trial with Nalbuphine ER in hemodialysis patients with uremic pruritus.

[Read More]

Trevi releases phase II/III uremic pruritus results

Monday, September 14, 2015

Trevi Therapeutics, a New Haven, Conn.-based late-stage clinical development company developing oral Nalbuphine ER for chronic pruritus conditions, has announced statistically significant results from its phase II/III trial for the treatment of moderate to severe uremic pruritus. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality, and currently has no approved therapies in the U.S. or Europe. Nalbuphine ER has a dual mechanism of action, as it is a mu receptor antagonist and kappa receptor agonist, and both mechanisms have been separately shown to be effective in abolishing itch.

[Read More]